Precision Biosciences Stock Performance
| DTIL Stock | USD 3.96 0.03 0.75% |
The company holds a Beta of 0.8, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Precision BioSciences' returns are expected to increase less than the market. However, during the bear market, the loss of holding Precision BioSciences is expected to be smaller as well. At this point, Precision BioSciences has a negative expected return of -0.93%. Please make sure to check Precision BioSciences' total risk alpha, as well as the relationship between the skewness and day median price , to decide if Precision BioSciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Precision BioSciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain quite persistent which may send shares a bit higher in March 2026. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return (0.63) | Five Day Return (6.38) | Year To Date Return (3.41) | Ten Year Return (99.24) | All Time Return (99.24) |
Last Split Factor 1:30 | Last Split Date 2024-02-14 |
1 | Precision BioSciences Announces 75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants | 11/10/2025 |
2 | How Precision BioSciences Inc. stock compares with market leaders - July 2025 Decliners Daily Stock Trend Reports - Newser | 12/02/2025 |
3 | Aug Summary Can Precision BioSciences Inc stock hit analyst price targets - Weekly Trading Summary Reliable Breakout Stock Forecasts - moha.gov.vn | 12/11/2025 |
4 | Acquisition by Brown Melinda of 1381 shares of Precision BioSciences at 4.97 subject to Rule 16b-3 | 12/15/2025 |
5 | Acquisition by Frankel Stanley of 2700 shares of Precision BioSciences at 4.7 subject to Rule 16b-3 | 12/16/2025 |
6 | Insider Buying Precision BioSciences Director Acquires 12,690.00 in Stock - MarketBeat | 12/17/2025 |
7 | Acquisition by Michael Amoroso of 9443 shares of Precision BioSciences subject to Rule 16b-3 | 12/19/2025 |
8 | Precision Biosciences Inc files for mixed shelf of up to 250 million - SEC filing - marketscreener.com | 12/30/2025 |
9 | Precision BioSciences Tiny Gene-Editing Stock Caught Between Deep Cuts and Big Optionality - AD HOC NEWS | 01/05/2026 |
10 | Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGE... | 01/12/2026 |
11 | Aug Levels How does Precision BioSciences Inc perform in inflationary periods - 2025 Dividend Review Fast Gain Swing Alerts - baoquankhu1.vn | 01/15/2026 |
12 | Disposition of 2500 shares by Smith J. Jefferson of Precision BioSciences subject to Rule 16b-3 | 01/20/2026 |
13 | Disposition of 10200 shares by Smith J. Jefferson of Precision BioSciences at 4.03 subject to Rule 16b-3 | 01/21/2026 |
14 | Disposition of 34799 shares by Michael Amoroso of Precision BioSciences at 4.17 subject to Rule 16b-3 | 01/22/2026 |
15 | Disposition of 964 shares by Michael Amoroso of Precision BioSciences at 5.56 subject to Rule 16b-3 | 01/27/2026 |
| Begin Period Cash Flow | 116.7 M | |
| Total Cashflows From Investing Activities | -215 K |
Precision | Build AI portfolio with Precision Stock |
Precision BioSciences Relative Risk vs. Return Landscape
If you would invest 736.00 in Precision BioSciences on November 2, 2025 and sell it today you would lose (340.00) from holding Precision BioSciences or give up 46.2% of portfolio value over 90 days. Precision BioSciences is currently does not generate positive expected returns and assumes 3.8808% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Precision, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Precision BioSciences Target Price Odds to finish over Current Price
The tendency of Precision Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.96 | 90 days | 3.96 | about 83.1 |
Based on a normal probability distribution, the odds of Precision BioSciences to move above the current price in 90 days from now is about 83.1 (This Precision BioSciences probability density function shows the probability of Precision Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Precision BioSciences has a beta of 0.8 suggesting as returns on the market go up, Precision BioSciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Precision BioSciences will be expected to be much smaller as well. Additionally Precision BioSciences has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Precision BioSciences Price Density |
| Price |
Predictive Modules for Precision BioSciences
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Precision BioSciences. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Precision BioSciences Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Precision BioSciences is not an exception. The market had few large corrections towards the Precision BioSciences' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Precision BioSciences, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Precision BioSciences within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.74 | |
β | Beta against Dow Jones | 0.80 | |
σ | Overall volatility | 1.19 | |
Ir | Information ratio | -0.16 |
Precision BioSciences Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Precision BioSciences for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Precision BioSciences can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Precision BioSciences generated a negative expected return over the last 90 days | |
| Precision BioSciences has high historical volatility and very poor performance | |
| Precision BioSciences has high likelihood to experience some financial distress in the next 2 years | |
| Precision BioSciences currently holds about 184.14 M in cash with (58.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Latest headline from MacroaxisInsider: Disposition of 964 shares by Michael Amoroso of Precision BioSciences at 5.56 subject to Rule 16b-3 |
Precision BioSciences Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Precision Stock often depends not only on the future outlook of the current and potential Precision BioSciences' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Precision BioSciences' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 6.9 M | |
| Cash And Short Term Investments | 86.3 M |
Precision BioSciences Fundamentals Growth
Precision Stock prices reflect investors' perceptions of the future prospects and financial health of Precision BioSciences, and Precision BioSciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Precision Stock performance.
| Return On Equity | -2.05 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 79.1 M | ||||
| Shares Outstanding | 24.07 M | ||||
| Price To Earning | (6.10) X | ||||
| Price To Book | 5.70 X | ||||
| Price To Sales | 137.43 X | ||||
| Revenue | 68.7 M | ||||
| Gross Profit | 698 K | ||||
| EBITDA | 13.53 M | ||||
| Net Income | 7.17 M | ||||
| Cash And Equivalents | 184.14 M | ||||
| Cash Per Share | 1.66 X | ||||
| Total Debt | 30.05 M | ||||
| Debt To Equity | 0.27 % | ||||
| Current Ratio | 4.59 X | ||||
| Book Value Per Share | 1.38 X | ||||
| Cash Flow From Operations | (58.45 M) | ||||
| Earnings Per Share | (8.96) X | ||||
| Market Capitalization | 95.93 M | ||||
| Total Asset | 136.39 M | ||||
| Retained Earnings | (482.46 M) | ||||
| Working Capital | 80.01 M | ||||
| Current Asset | 174.05 M | ||||
| Current Liabilities | 23.86 M | ||||
About Precision BioSciences Performance
By examining Precision BioSciences' fundamental ratios, stakeholders can obtain critical insights into Precision BioSciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Precision BioSciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | (0.25) | (0.26) | |
| Return On Assets | 0.05 | 0.05 | |
| Return On Equity | 0.13 | 0.15 |
Things to note about Precision BioSciences performance evaluation
Checking the ongoing alerts about Precision BioSciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Precision BioSciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Precision BioSciences generated a negative expected return over the last 90 days | |
| Precision BioSciences has high historical volatility and very poor performance | |
| Precision BioSciences has high likelihood to experience some financial distress in the next 2 years | |
| Precision BioSciences currently holds about 184.14 M in cash with (58.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.66. | |
| Latest headline from MacroaxisInsider: Disposition of 964 shares by Michael Amoroso of Precision BioSciences at 5.56 subject to Rule 16b-3 |
- Analyzing Precision BioSciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Precision BioSciences' stock is overvalued or undervalued compared to its peers.
- Examining Precision BioSciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Precision BioSciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Precision BioSciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Precision BioSciences' stock. These opinions can provide insight into Precision BioSciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Precision BioSciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. Projected growth potential of Precision fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Precision BioSciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (8.96) | Revenue Per Share | Quarterly Revenue Growth (0.98) | Return On Assets | Return On Equity |
Precision BioSciences's market price often diverges from its book value, the accounting figure shown on Precision's balance sheet. Smart investors calculate Precision BioSciences' intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Precision BioSciences' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Precision BioSciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Precision BioSciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.